In this interview, Novartis CEO Vas Narasimhan sits down with CNNMoney Switzerland’s Urs Gredig and shares why he thinks innovation should come from the bottom and how wearing jeans and no tie help make him a better executive. He also discusses his first year on the job and his strategy moving forward.
In this Bloomberg interview, Vas Narasimhan, CEO of Novartis shares his thoughts on how medicines can have a transformative effect.
In this interview with Susie Gharib from Fortune, Vas Narasimhan, CEO of Novartis, shares his perspective on changing the culture within Novartis.
In this episode of CNN`s special HR series, Steven Baert, Chief People & Organization Officer, shares the challenges that Novartis is facing as it turns its management style on its head and fosters an “unbossed” corporate culture.
Novartis ranks #4 in Fortune Magazine’s Most Admired Companies Pharmaceutical Industry list.
In this a16z podcast, bio general partners Jorge Conde and Vijay Pande with Sonal Chokshi interview Vas Narasimhan, CEO of Novartis, on some questions, challenges and opportunities that we’re facing in the pharma industry today.
Deaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could avert this tragedy with decisive action.
Cameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable medicines and educating patients.
Novartis was ranked 4th in Fortune magazine’s Change the World list and cited for developing an innovative new cancer treatment, working to expand access to healthcare and supporting value-based pricing.
Novartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch Novartis Access.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.
This site is intended for a global audience.